CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Inclusion Criteria: Myelodysplastic Syndrome (MDS) having failed hypomethylating agent (HMA) therapy cohort: * Age 18-79 years, inclusive * Pathologically confirmed MDS or myelodysplastic/myeloproliferative overlap (MDS/MPN) * IPSS-R score intermediate, high or very high * Must have failed therapy with an HMA (defined as lack of response by International Working Group criteria (1) or intolerance of the drug) Secondary Acute Myeloid Leukemia (sAML): * Pathologically confirmed AML according to World Health Organization (WHO) criteria * Evidence of an antecedent hematologic disorder (AHD) prior to acute leukemia including a known prior diagnosis of MDS, MPN or MDS/MPN or data suggestive of an AHD such as cytopenias, fibrosis, macrocytic anemia, cellular or dysplasia at or prior to the time of diagnosis. If available, MDS-defining karyotypes (-7/del(7q), -5/del(5q), del(13q), del(11q), del(12p), t(12p), del(9q), idic(X)(q13), t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p), t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34)) or somatic mutations in multiple genes including p53, TET2, JAK2, CALR, MPL, ASXL1, RUNX1, SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 would also confirm eligibility. * Age 60-79 years, inclusive * May be previously untreated For both cohorts: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Deemed eligible to receive cytotoxic chemotherapy *…